Barry, OppHub America Desk · · Source: yahoo-finance
Medtronic (MDT) Turnaround Story? UBS Upgrades to Buy
- upgraded Medtronic (: ) to Buy, citing a turnaround story and strong revenue growth. - Investors are watching for continued execution across Medtronic's portfolio to confirm sustained growth.
Based on reporting from yahoo-finance.
Medtronic (NYSE: MDT) is showing signs of a turnaround, with UBS upgrading shares to Buy, citing a return to sustainable growth. The company reported its highest annual revenue growth in 10 years in fiscal Q4 2026, reaching $9.8 billion in Q4 and $36.4 billion for the full year.
Market context for this story
As of: WeekendLoading quotes…
Informational only — not investment advice. Full markets →
Medtronic·$MDT$MDTMedtronic
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/MDT. Not investment advice.
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
**Implied Volatility / Movement:** **
Medtronic (NYSE: MDT) is emerging as a potential turnaround story, prompting UBS to upgrade its rating to Buy from Neutral, according to a research note on Sunday, August 9, 2026. The upgrade hinges on the company's recent fiscal Q4 and full-year 2026 results, which demonstrated the highest annual revenue growth in a decade.
Fiscal Q4 revenue reached $9.8 billion, an increase of 9.9% as reported and 6.6% organically. For the full fiscal year 2026, revenue totaled $36.4 billion, with adjusted revenue at $36.3 billion, up 8.4% as reported and 5.8% organically. Medtronic's cardiac segment, particularly Cardiac Ablation Solutions, showed significant strength, with revenue up 78% globally and 124% in the U.S. The company is also investing in innovation and high-growth areas like ICE catheter technology and has seen its Symplicity Spyral hypertension device annualize at $100 million. While momentum is positive, some analysts suggest waiting for sustained multi-quarter execution to confirm the turnaround's completion, noting that growth has been concentrated in a few key products.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: August 9, 2026 at 7:59 PM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
medical device turnaround
A major Wall Street firm upgraded medical device maker Medtronic because its sales grew faster than they have in ten years. People investing money care because this could mean the company is finally fixing its past sluggishness and entering a period of steady growth.
What changed
UBS upgraded Medtronic to Buy citing record annual revenue growth and strong momentum in cardiac medical devices.
Who wins / who loses
Medtronic and its shareholders benefit from accelerating product demand, while legacy medical device competitors may lose market share in high-growth cardiac niches.
Time horizon
Think in terms of the next few months.
Confidence & best fit
medium confidence · Long-term investor
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $MDTBuild slowly — only if it fits your plan
Medtronic is making more money than it has in years, which could mean its stock is a good buy for the long haul.
View $MDT chart → · End-of-day delayed data
Peer
- $ABTWatch — track, don’t rush
Other big healthcare companies like Abbott might see investors compare their growth to Medtronic's new success.
View $ABT chart → · End-of-day delayed data
- $BSXWatch — track, don’t rush
Boston Scientific competes directly in heart treatments and will have to work harder to keep up with Medtronic's hot products.
View $BSX chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Direction: bullish · Style: Bullish defined-risk call idea · Level: intermediate
Beginners should skip options here and stick to regular stock shares, as options can expire worthless if the turnaround loses steam.
Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Research specialized medical equipment suppliers and component providers benefiting from increased cardiac procedure volumes.
What would break this thesis
- Subsequent quarterly earnings showing deceleration in cardiac segment growth or margin compression.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from yahoo-finance.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).